Pershing Square Sohn Cancer Prize
Pershing Square Sohn Cancer Prize supports early-career independent scientists pursuing bold, high-risk cancer research to advance understanding, diagnosis, prevention, or treatment across the United States.
Browse similar grants
Funder: Pershing Square Philanthropies
Due Dates: October 26, 2026, at 5:00 p.m. ET (Letter of Intent) | April 13–14, 2027 (Finalist presentations) | July 1, 2027 (Project start)
Funding Amounts: $750,000 over three years ($250,000 annually)
Summary: Supports early-career independent scientists pursuing radically innovative, high-risk, high-reward cancer research across the United States.
Key Information: Lead investigators must have two to six years of independent laboratory experience by July 2027.
Description
The Pershing Square Sohn Cancer Prize is an initiative of the Pershing Square Sohn Cancer Research Alliance (PSSCRA), supported by Pershing Square Philanthropies. It gives early-career scientists freedom to pursue bold cancer research when traditional funding may be lacking. Since 2026, the prize has expanded beyond the greater New York City area to institutions across the United States.
The program seeks radically innovative, scientifically sound projects with strong biological rationales and high-risk, high-reward potential. Work may include basic research and technological applications that advance understanding, diagnosis, prevention, or treatment of cancer. Proposals should address important questions or unmet needs and explain why the work merits funding now. This single-investigator award encourages collaboration, while centering review on the lead scientist’s accomplishments, background, and proposed research.
